In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y
- PMID: 38560908
- DOI: 10.7326/J24-0016
In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y
Abstract
Ray KK, Nicholls SJ, Li N, et al; CLEAR OUTCOMES Committees and Investigators. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024;12:19-28. 38061370.
Conflict of interest statement
Comment on
-
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial.Lancet Diabetes Endocrinol. 2024 Jan;12(1):19-28. doi: 10.1016/S2213-8587(23)00316-9. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061370 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical